Search
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigationalAlmonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigationalBelumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cl...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesCinchonidine
go.drugbank.com/drugs/DB16831ExperimentalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsRemibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalRemibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersTyrosol
go.drugbank.com/drugs/DB16855ExperimentalSynonyms: p-TyrosolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLinzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigationalLinzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to ...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 SubstratesNorclobazam
go.drugbank.com/drugs/DB17092InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesZiftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigationalZiftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates